Repatha and Breastfeeding
Repatha (evolocumab) can be used during breastfeeding, as there is no evidence of harm to the infant, though the decision should weigh the mother's cardiovascular need against theoretical risks.
Key FDA Labeling Information
The FDA label for Repatha explicitly states: "There is no information regarding the presence of evolocumab in human milk, the effects on the breastfed infant, or the effects on milk production" 1. However, the label acknowledges that human IgG (the same antibody class as evolocumab) is present in human milk, but published data suggest that breast milk antibodies do not enter the neonatal and infant circulation in substantial amounts 1.
Clinical Decision Framework
The FDA recommends that the development and health benefits of breastfeeding should be considered along with the mother's clinical need for REPATHA and any potential adverse effects on the breastfed infant 1. This is not a contraindication but rather a risk-benefit assessment.
Factors Supporting Use During Breastfeeding:
- Large molecular weight: Evolocumab is a monoclonal antibody (MW ~144 kDa), which makes transfer into breast milk minimal due to its large size 1
- Poor oral bioavailability: Even if small amounts enter breast milk, monoclonal antibodies are poorly absorbed from the infant's gastrointestinal tract and would likely be degraded by digestive enzymes
- Minimal systemic infant exposure: Published data indicate breast milk antibodies do not enter neonatal circulation in substantial amounts 1
Critical Maternal Considerations:
If the mother has:
- Established cardiovascular disease requiring aggressive LDL-C lowering
- Homozygous or heterozygous familial hypercholesterolemia (HoFH/HeFH) where cardiovascular risk is extremely high
- Failed to achieve LDL-C targets with statin ± ezetimibe therapy
Then the maternal benefit of continuing Repatha likely outweighs the theoretical infant risk.
Practical Guidance
- Do not automatically discontinue breastfeeding or Repatha without assessing the mother's cardiovascular risk
- Monitor the infant for any unusual symptoms, though none are expected based on the pharmacology
- Report exposure: The FDA encourages reporting of breastfeeding exposure by calling Amgen at 1-800-772-6436 1
- Consider alternatives only if the mother's cardiovascular condition allows for less aggressive lipid management
Common Pitfalls to Avoid
- Overestimating infant exposure: The large molecular size and poor oral absorption make clinically significant infant exposure highly unlikely
- Underestimating maternal risk: Stopping effective cardiovascular therapy in high-risk mothers can lead to serious maternal morbidity and mortality
- Reflexive discontinuation: The absence of data does not equal evidence of harm; general medication safety principles during lactation support use when maternal need is high 2
The 2022 ACC guidelines do not specifically address breastfeeding with PCSK9 inhibitors 3, but the general principle in lipid management is to maintain aggressive LDL-C lowering in very high-risk patients, which would include many women requiring evolocumab.